Zura Bio Limited (NASDAQ:ZURA – Get Free Report) Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Zura Bio Stock Performance
Shares of NASDAQ ZURA opened at $3.62 on Friday. The firm’s 50-day moving average price is $3.69 and its 200-day moving average price is $3.77. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $7.22.
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Analysts anticipate that Zura Bio Limited will post -0.53 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on ZURA
Institutional Trading of Zura Bio
Several hedge funds have recently made changes to their positions in the business. Great Point Partners LLC raised its position in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Armistice Capital LLC grew its holdings in Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Zura Bio during the 2nd quarter valued at about $8,446,000. Affinity Asset Advisors LLC bought a new position in Zura Bio during the 1st quarter valued at about $1,157,000. Finally, Bank of New York Mellon Corp grew its holdings in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares during the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Articles
- Five stocks we like better than Zura Bio
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What Are Dividend Challengers?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- How to Invest in Biotech Stocks
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.